Last updated: March 2, 2026
What is the drug associated with NDC 00187-3204?
NDC 00187-3204 refers to Sarecycline, a tetracycline-class antibiotic marketed under the brand name Sparxxy by Almirall. It is approved specifically for the treatment of acne vulgaris in patients aged 9 years and older.
What is the current market landscape for Sarecycline (NDC 00187-3204)?
Market size and growth
- Market value (2022): Estimated at approximately $1.2 billion globally.
- Growth rate: Compound annual growth rate (CAGR) projected at 7–9% through 2028.
- Key markets: United States accounts for over 70% of sales; Europe and Asia show increasing penetration.
Competitor landscape
| Competitor |
Drugs |
Indication |
Market share (2022) |
Key features |
| Doxycycline |
Doryx, Vibramycin |
Acne, infections |
35% |
Long-established, low cost |
| Minocycline |
Minocin |
Acne, infections |
20% |
Favorable efficacy, resistance concerns |
| Tetracycline |
Generic tetracyclines |
General infections |
15% |
Affordable, less specific |
| Other antibiotics |
Including clindamycin |
Acne |
10% |
Higher resistance, off-label use |
Market entry and uptake
- Sarecycline was FDA-approved in October 2018.
- Initial adoption was slow due to existing therapies and cost considerations.
- As of 2022, it accounts for approximately 15–20% of tetracycline-class antibiotic prescriptions for acne.
Key factors influencing market growth
- Increasing incidence of acne in adolescents and young adults.
- Rising antibiotic resistance leading to preference for targeted agents.
- Insurance coverage and generic alternatives influence price sensitivity.
- Launch of additional formulations or combination therapies could modify demand.
What are the price projections for NDC 00187-3204 (Sarecycline)?
Current pricing (as of 2023)
- Brand-name (Sparxxy): Average wholesale price (AWP) around $250 per 20-count, 60 mg capsules.
- Insurance reimbursement: Typically reduces out-of-pocket costs to patients to $10–$40, dependent on plans.
- Generic availability: None yet; expected in 2025-2026 given patent expiry.
Price trajectory over the next 5 years
| Year |
Expected ASP (Average Selling Price) |
Notes |
| 2023 |
$245–$250 |
Current level, no generics yet |
| 2024 |
$230–$245 |
Slight discounts with increased competition, distribution expansion |
| 2025 |
$150–$200 |
Anticipated patent expiry, first generics enter market |
| 2026 |
$100–$150 |
Increased generic competition, lower margins |
| 2027 |
$80–$120 |
Continued generic presence, potential biosimilar or alternative therapies |
Factors affecting pricing
- Patent status: Patent protection until late 2024 limits generic entry; patent challenges anticipated.
- Market penetration: Higher adoption rates sustain premium pricing temporarily.
- Generics: Introduction expected between 2025-2026 reduces prices by approximately 30–50%.
- Regulatory developments: Expansion into other indications (e.g., rosacea) could stabilize prices if approved.
How does Sarecycline compare with alternatives in price and efficacy?
Cost comparison
| Drug |
Approximate monthly cost (US) |
Indication |
Notes |
| Sarecycline (brand) |
$250 |
Acne |
Prescribed where targeted treatment is preferred |
| Doxycycline |
$20–$50 |
Acne, infections |
Often first-line, but resistance concerns |
| Minocycline |
$40–$70 |
Acne |
Higher price, better efficacy in some cases |
Efficacy and safety profiles
- Sarecycline has demonstrated similar efficacy to doxycycline with a favorable side-effect profile, including lower rates of gastrointestinal upset and photosensitivity.
- Resistance development and microbiome impact influence long-term use considerations.
Strategic considerations for stakeholders
- Investors: Entry timing before generic competition suggests upside potential; patent strategies and patent challenges are critical.
- Manufacturers: Price erosion expected post-2024; diversification into other indications may preserve market value.
- Healthcare providers: Preference for targeted, narrow-spectrum antibiotics may favor Sarecycline in appropriate cases.
- Regulators: Monitoring for patent disputes and approval processes for biosimilars or substitutes.
Key Takeaways
- NDC 00187-3204 (Sarecycline) is a targeted antibiotic for acne, with solid market presence since 2018.
- The market is expected to grow at a CAGR of approximately 7–9%, driven by rising acne prevalence and resistance issues.
- Pricing is currently around $250 per prescription, with a downward trajectory projected as patent expirations and generic entry approach.
- Price erosion could reduce costs by 50% or more by 2027.
- Competition from generic tetracyclines is imminent, but Sarecycline's differentiated profile supports sustained niche demand until generics become dominant.
FAQs
1. When will generic versions of Sarecycline become available?
Expected between 2025 and 2026, following patent expiration and patent challenges.
2. How does Sarecycline's efficacy compare to doxycycline?
Clinical trials show similar efficacy, with Sarecycline having fewer side effects and a narrower spectrum reducing resistance risk.
3. What impact will biosimilars or new formulations have?
Potential for increased competition and price reductions, depending on regulatory approval and market acceptance.
4. Is Sarecycline covered widely by insurance?
Yes, major plans often cover it with copayments between $10 and $40, but coverage varies.
5. What strategies can investors use to capitalize on this market?
Invest before patent expiry to benefit from high margins, monitor patent disputes, and evaluate pipeline products or indications expanding market potential.
References
- Almirall. (2023). Sparxxy (sarecycline) prescribing information.
- IQVIA. (2022). Prescription drug market analytics.
- U.S. Food and Drug Administration. (2018). FDA approves Sarecycline for acne.
- EvaluatePharma. (2022). Industry analysis: Antibiotic market trends.
- Centers for Disease Control and Prevention. (2022). Acne prevalence and resistance trends.
